

6. Literatur

1. Pounder RE, Ng D. The prevalence of *Helicobacter pylori* infection in different countries. *Aliment Pharmacol Ther* 9 (1995) 9 (Suppl 2): 33-39
1. Peterson WL. *Helicobacter pylori* and peptic ulcer disease. *N Engl J Med* (1991) 324:1043-1048
2. Wotherspoon AC, Ortiz-Hildago C, Falzon MR, Isaacson PG. *Helicobacter pylori*-associated gastritis and primary B-cell gastric lymphoma. *Lancet* (1991)338:1175-76
3. Parsonnet J, Friedmann GD, Vandersteen DP, Chan Y, Vogelma JH, Orentreich N, Sibley RK. *Helicobacter pylori* infection and the risk of gastric carcinoma. *N Engl J Med* (1991) 325:1127-1131
4. Marshall BJ, Warren JR. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. *Lancet* (1983) I: 1273- 1275
5. Coghlan JG, Gilligan D, Humphries H, McKenna D, Dooley C, Sweeny E, Keane C, O'Morain C: *Campylobacter pylori* and recurrence of duodenal ulcers – a 12-month follow-up study. *Lancet* 2(1987):1109-1111
6. Krienitz W. Über das Auftreten von Spirochäten verschiedener Form im Mageninhalt bei Carcinoma ventriculi. *Dtsch Med Wochenschr* (1906) 28:872-889
7. Günsburg F. Zur Kritik des Magengeschwürs, insbesondere des perforierenden. In: Vierordt K (Hg.) *Archiv für physiologische Heilkinde* (1852) 11:516-527
8. Virchow R. Historisches, Kritisches und Positives zur Lehre der Unterleibsaffektionen. In: *Archiv für pathologische Anatomie und Physiologie und für klinische Medizin* (1853) 5:281-375
9. Boettcher G. Zur Genese des perforierenden Magengeschwürs. *Dorpater Med Z* (1874) 5:148
10. Marshall BJ, Armstrong JA, McGeachie DB, Glancy RJ: Attempt to fulfil Koch's postulates for pyloric *Campylobacter*. *Med J Aust* (1985); 142:436-439
11. Morris A, Nicholson G. Ingestion of *Campylobacter pyloridis* causes gastritis and raised fasting gastric pH. *Am J Gastroenterol* (1987) 82:192-199
12. Goodwin CS, Armstrong JA, Chilvers T, Peters M, Collins MD, Sly L, McConnell W, Harper WES: Transfer of *Campylobacter pyloridis* and *Campylobacter mustelae* to *Helicobacter* gen. nov. as *Helicobacter pylori* comb. nov. and *Helicobacter mustelae* comb. nov., respectively. *International Journal of Systematic Bacteriology* (1989), 39: 397-405

13. Dunn BE, Cohen H, Blaser MJ. *Helicobacter pylori*. Clin Microbiol Rev (1997); 10:720-741
14. Kusters JG, Gerrits MM, Van Strijp JAG, Vandenbroucke-Grauls CMJE. Coccoid forms of *Helicobacter pylori* are the morphologic manifestation of cell death. Infect Immun (1997) 65:3672-3679
15. Suerbaum S, Josenhans C, Labigne A. Cloning and genetic characterization of the *Helicobacter pylori* and *Helicobacter mustelae* flaB flagellin genes and construction of *H. pylori* flaA- and flaB-negative mutants by electroporation-mediated allelic exchange. J Bakteriol (1993) 175:3278-3288
16. Solnick JV, Tompkins LS. *Helicobacter pylori* and gastroduodenal disease: pathogenesis and host-parasite interaction. Infect Agents Dis (1992)1:294-309
17. Suerbaum S, Maynard Smith J, Bapumia K, Morelli G, Smith NH, Kunstmann E, Dyrek I, Achtmann M: Free recombination within *Helicobacter pylori*. Proc Natl Acad Sci USA 95, 12619-12624 (1998)
18. Suerbaum S, Achtman M. Evolution of *Helicobacter pylori*: the role of recombination. Trends Microbiol (1999):191-195
19. Megraud F. Epidemiology of *Helicobacter pylori* infection. Gastroenterol Clin North Am (1993) 22: 73-88
20. Taylor DN, Blaser MJ. The epidemiology of *Helicobacter* infection. Epidemiol Rev (1991) 13: 42-59
21. Wyle FA. *Helicobacter pylori*: current perspectives. J Clin Gastroenterol (1991) 13 (Suppl 1): S114-S24
22. The Eurogast Study Group: Epidemiology of and risk factors for *Helicobacter pylori* infection among 3194 asymptomatic subjects in 17 population. Gut 43(1993)1672- 1676
23. Bode G, Rothenbacher D, Brenner H, Adler G. *Helicobacter pylori* and abdominal symptoms: a population-based study among preschool children in southern Germany. Pediatrics (1998) 101 (4 pt 1):634-637
24. Feldmann RA, Eccersley AJP, Hardie JM. Epidemiology of *Helicobacter pylori*: acquisition, transmission, Population and disease-to-infection ratio. Br Med Bull (1998) 54:39-53
25. Vaira D, Holton J, Ricci C, Menegatti M, Gatta L, Berardi S, Tampieri A, Miglioli M. The transmission of *Helicobacter pylori* from stomach to stomach. Aliment Pharmacol Ther (2001) 15 (Suppl. 1) 33-42

26. Sipponen P, Helske T, Jarvinen P, Hyvarinen H, Seppala K, Siurala M, Fall in the prevalence of chronic gastritis over 15 years: analysis of outpatient series in Finland from 1977, 1985, and 1992. *Gut* (1994) 35:1167- 1171
27. Redlinger T, O'Rourke K, Goodman KJ. Age Distribution of *Helicobacter pylori* seroprevalence among young children in a United States/Mexico border community: evidence for transitory infection. *Am J Epidemiol* (1999)150:225-230
28. Malaty HM, Graham DY. Importance of childhood socioeconomic status on the current prevalence of *Helicobacter pylori* infection. *Gut* (1994) 35:742-745
29. Malaty HM, Engstrand L, Petersen NL, Graham DY. *Helicobacter pylori* infection: Genetic and environmental influences. A study of twins. *Ann Intern Med* (1994) 120:982-986
30. Kuipers EJ, Thijs JC, Festen HPM. The prevalence of *Helicobacter pylori* in peptic ulcer disease. *Aliment Pharmacol Ther* (1995) 9 (Supp2):59-70
31. Atherton JC. *Helicobacter pylori* virulence factors. *Br Med Bull* (1998) 54: 105-120
32. Suerbaum S. Bakterielle Physiologie und Virulenzfaktoren. In: *Helicobacter pylori*- Von der Grundlage zur Therapie. Malfertheiner P. (Hrsg.), Georg Thieme Verlag, Stuttgart, New York, 3. Auflage (2000): 11-20
33. Dundon WG, de Bernard M, Montecucco C. Virulence factors of *Helicobacter pylori*. *Int J Med Microbiol* (2001) 290:647-658
34. Cover TL, Blaser MJ. Purification and characterisation of the vacuolating toxin from *Helicobacter pylori*. *J Biol Chem* (1992) 276:10570-10575
35. Cover TL, Tummuru MKR, Cao P, Thompson SA, Blaser MJ. Divergence of genetic sequences for the vacuolating cytotoxin among *Helicobacter pylori* strains. *J Biol Chem* (1994) 796:10566-10573
36. de Bernard M, Papini E, de Filipis V, Gottardi E, Telford J, Manetti R, Fontana R, Rappuoli R, Montecucco C. Low pH activates the vacuolating toxin of *Helicobacter pylori* which becomes acid and pepsin resistant. *J Biol Chem* (1995) 270:23937-23940
37. Leunk RD, Johnson PT, David BC, Kraft WG, Morgan DR. Cytotoxic activity in broth-culture filtrates of *Campylobacter pylori*. *J Med Microbiol* (1988) 26:93-99
38. Atherton JC, Cao P, Peek RM Jr, Tummuru MK, Blaser MJ, Cover TL. Mosaicism in vacuolating cytotoxin alleles of *Helicobacter pylori*: association of specific *vacA* types with cytotoxin production and peptic ulceration. *J Biol Chem* (1995)270:17771-17777
39. Atherton JC, Peek RM, Tham KT, Cover TL, Blaser MJ. Clinical and pathological importance of heterogeneity in *vacA*, the vacuolating cytotoxin gene of *Helicobacter pylori*. *Gastroenterology* (1997) 112:92-99

40. Covacci A, Censini S, Bugnoli M, Petracca R, Burroni D, Macchia G, Massone A, Papini E, Xiang Z, Figura N, Rappuoli R. Molecular characterisation of the 128-kDa immunodominant antigen of *Helicobacter pylori* associated with cytotoxicity and duodenal ulcer. *Proc. Natl. Acad. Sci. USA* (1993) 90:5791-5795
41. Peek RM, Miller GG, Tham KT, Perez-Perez GI, Zhao X, Atherton JC, Blaser MJ. Heightened inflammatory response and cytokine expression in vivo to *cagA*⁺ *Helicobacter pylori* strains. *Lab Invest* (1995) 73:760-770
42. Tummuru MKR, Cover TL, Balser MJ. Mutation of the cytotoxin-associated *cagA* gene does not affect the vacuolating cytotoxin activity of *Helicobacter pylori*. *Infect Immun* (1994) 62:2609-2613
43. Maeda S, Ogura K, Yoshida H, Kanai F, Ikenoue T, Kato N, Shiratori Y, Omata M. Major virulence factors, *VacA* and *CagA*, are commonly positive in *Helicobacter pylori* isolates in Japan. *Gut* (1998), 42:338-343
44. Nomura AMY, Perez-Perez GI, Lee J, Stemmermann G, Blaser MJ. Relation between *Helicobacter pylori cagA* status and risk of peptic ulcer disease. *Am J Epidemiol* (2002) 155:1054-1059
45. Parsonnet J, Friedmann GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with *CagA* positive and *CagA* negative *Helicobacter pylori* infection. *Gut* (1997) 40:297-301
46. Eck M, Schmaußer W, Haas R, Greiner A, Czub S, Müller-Hermelink HK. MALT-type lymphoma of the stomach is associated with *Helicobacter pylori* strains expressing the *cagA* protein. *Gastroenterology* (1997) 112:1482-1486
47. Censini S, Lange C, Xiang Z, Crabtree JE, Ghiara P, Borodovsky M, Rappuoli R, Covacci A. *Cag*, a pathogenicity island of *Helicobacter pylori* encodes type I-specific and disease-associated virulence factors. *Proc Natl Acad Sci USA* (1996) 93: 14648-14653
48. Covacci A, Rappuoli A. Tyrosine-phosphorylated bacterial proteins: trojan horses for the host cell. *J Exp Med* (2000) 191:587, 592
49. Covacci A, Telford JL, Del Giudice G, Parsonnet J, Rappuoli R. *Helicobacter pylori* virulence and genetic geography. *Science* (1999) 284:1328-33
50. Segal ED, Cha J, Lo J, Falkow S, Tompkins LS. Altered states: involvement of phosphorylated *CagA* in the induction of host cellular growth changes by *Helicobacter pylori*. *Proc Natl Acad Sci USA* (1999) 96:14559-14564
51. Morris A, Nicholson G. Ingestion of *Campylobacter pyloridis* causes gastritis and raises fasting gastric pH. *Am J Gastroenterol* (1987) 82:192-199

52. Crabtree JE, Lindley IJ. Mucosal interleukin-8 and Helicobacter associated disease. *Eur J Gastroenterol Hepatol* (1994) 6:33-38
53. Dooley CP, Cohen H, Fitzgibbons PL, Bauer M, Appleman MD, Perez-Perez GI, Blaser MJ. Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. *N Engl J Med* (1989) 321:1562-1566
54. Go MF. What are the host factors that place an individual at risk for Helicobacter pylori associated disease? *Gastroenterology* (1997) 113:S15-S20
55. D'Elia MM, Andersen LP, Del Prete G. Inflammation and host response. *Curr Opin Gastroenterol* (1998)15 (Suppl):S15-S19
56. Langenberg W, Rauws EA, Houthoff HJ, Dubbier JH, Van Boehmen CG, Tytgat GN. Follow-up study of individuals with untreated Campylobacter pylori associated gastritis and of non-infected persons with non-ulcer dyspepsis. *J Infect Dis* (1988) 157:1245-1249
57. Azuma T, Konishi J, Tanaka Y, Hirai M, Ito S, Kohli Y. Contribution of HLA-DQA to host's response against Helicobacter pylori. *Lancet* (1994) 343:542-543
58. Kirchner T, Faller G. Pathologie und Autoimmunpathogenese der Helicobacter pylori-Gastritis. In: Kirchner T, Lemcke B, Kist M (Hg.) *Ökosystem Darm*. Springer-Verlag Heidelberg (1999): 155-162
59. Moss SF, Bishop AE, Polak JM, Calam J. Effect of H. pylori on gastric somatostatin in duodenal ulcer disease. *Lancet* (1992) 340:930-932
60. Carrick J, Lee A, Hazell S, Ralston M, Daskalopoulos G. Campylobacter pylori, duodenal ulcer and gastric metaplasia: possible role of functional heterotopic tissue in ulcerogenesis. *Gut* (1989) 30: 790-797
61. Crabtree JE, Taylor JD, Wyatt JI, Heathley RV, Shallcross TM, Tompkins DS, Rathbone BJ. Mucosal IgA, recognition of Helicobacter pylori 120kDA protein, peptic ulceration, and gastric pathology. *Lancet* (1995) 338:332-335
62. Rathbone BJ, Wyatt JI, Worsley BW, Shires SI, Trejdosiewicz LK, Haetley RV, Lowosky MS. Systemic and local antibody response to gastric Campylobacter pyloridis in non-ulcer dyspepsia. *Gut* (1986) 27:642-647
63. Herbrink P, van Doorn LJ. Serological Methods of Helicobacter pylori Infection and Monitoring of Eradication Therapy. *Eur J Clin Microbiol Infect Dis* (2000)19:164-173
64. Jokowski TD, Martins TB, Hill HR, Litwin CM. Immunoglobulin A antibodies to Helicobacter pylori. *J Clin Microbiol* (1997) 35:2999-3000
65. Lerang F, Haug JB, Moum JB, Mowinckel P, Berge T, Rahnildstveit E, Bjorneklett A. Accuracy of IgG serology and other tests in confirming Helicobacter pylori eradication. *Scan J Gastroenterol* (1998) 33:710-715

66. Laheij RJ, Witteman EM, Bloembergen P, de Koning RW, Jansen JBMJ, Verbeek AML. Short-term follow-up by serology of patients given antibiotic treatment for *Helicobacter pylori* infection. *J Clin Microbiol* (1998)36:1193-1196
67. Tosi MF, Czinn SJ. Opsonic activity of specific human IgG against *Helicobacter pylori*. *J Infect Dis* (1990)162:156-162
68. Gonzalez-Valencia G, Perez-Perez GI, Washburn RG, Blaser MJ. Susceptibility of *Helicobacter pylori* to the bactericidal activity of human serum. *Helicobacter* (1996) 1:28-33
69. Israel DA, Peek RM. Pathogenesis of *Helicobacter pylori*-induced gastric inflammation. *Aliment Pharmacol Ther* (2001)15:1271-1290
70. Negrini R, Lisato L, Zanella I, Cavazzini L, Gullini S, Villanacci V, Poiesi C, Albertini A, Ghielmi S. *Helicobacter pylori* infection induces antibodies cross-reacting with human gastric mucosa. *Gastroenterol* (1991) 101: 437-445
71. Malfertheiner P, Stolte M. Morphologie der *Helicobacter pylori* Gastritis. In: Malfertheiner P (Hg.) *Helicobacter pylori - Von der Grundlage zur Therapie*. Thieme Stuttgart, New York (2000): 49
72. Genta RM, Lew GM, Graham DY. Changes in the gastric mucosa following eradication of *Helicobacter pylori*. *Mod Path* (1993) 6:281-289
73. Valle J, Seppala K, Sipponen P, Kosunen T. Disappearance of gastritis after eradication of *Helicobacter pylori*. A morphometric study. *Scan J Gastroenterol* (1991) 26:1057-1056
74. Appelmek BJ, Faller G, Claeys D, Kirchner T, Vandenbroucke-Grauls CM. Bugs on trial: the case of *Helicobacter pylori* and autoimmunity. *Immunol Today* (1998)19:549-544
75. The Europeygast Study. Risk factors for atrophic chronic gastritis in a european population: results of the Europeygast study. *Gut* (2002) 50:779-785
76. Sande N, Nikilin M, Nilsson I, Wadstöm F, Laxen F, Harkönen M, Suovaniemi O, Sipponen P. Increased risk of developing atrophic chronic gastritis in patients infected with *cagA* positive *Helicobacter pylori*. *Scand J Gastroenterol* (2001)36:928-933
77. Henriksen TH. Peptic ulcer disease is strongly associated with *Helicobacter pylori* in east, west, central and South Africa. *Scand J Gastroenterol* (2001) 36: 561-564
78. Walsh JH, Petersen WL. The treatment of *Helicobacter pylori* infection in the management of peptic ulcer disease. *N Engl J Med* (1995)333:984-991

79. Berstad K, Berstad A. Helicobacter pylori infection in peptic ulcer disease. *Scand J Gastroenterol* (1993)28:561-567
80. Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. *Aliment Pharmacol Ther* (1995) 9 (Suppl. 2):59-69
81. Suerbaum S, Hur C, Josenhans C, Michetti P. Pathogenesis and virulence factors of Helicobacter pylori. *The year in Helicobacter pylori* (1999). Hg.: Malferteiner P et al
82. Rauws EA, Tygnat GN. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. *Lancet* (1990) 335:1233-1235
83. van der Hulst RW, Rauws EA, Koycu B, Keller JJ, Bruno MJ, Tijssen JG, Tygat GN. Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective, long-term follow-up study. *Gastroenterology* (1997) 113:1082-1086
84. Mukhopadhyay P. Gastric cancer and lymphoma. In: Westblom TU, Czinn SJ, Nedrud JG (Hsg.) *Gastrointestinal disease and Helicobacter pylori*, Springer, Berlin, Heidelberg, New York: 57-69
85. Zhang ZW, Patchett SE, Perret D, Katelaris PH, Domizio P, Farthing MJ The relation between gastric vitamin C concentrations, mucosal histology, and CagA seropositivity in the stomach. *Gut* (1998) 43:322-326
86. The Eurogast Study Group. An international association between Helicobacter pylori and infection and gastric cancer. *Lancet* (1993)341:1359-62
87. International Agency für Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans*, 61. Lyon, France: IARC (1994)
88. Wotherspoon AC, Ortiz-Hildago C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. *Lancet* (1991)338:1175-76
89. Doglioni C, Wotherspoon AC, Noschini A, Do Boni M, Isaacson PG. High incidence of primary gastric lymphoma in northeastern Italy. *Lancet* (1992)339:834-35
90. Genta RM, Kapur V, Graham DY, Musser JM. Gastric lymphoid follicles in Helicobacter pylori infection: frequency, distribution, and response to triple therapy. *Hum Pathol* (1993) 24:577
91. Stolte M. Helicobacter pylori gastritis and gastric MALT-lymphoma. *Lancet* (1992)339:745
92. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, Isaacson PG. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue after eradication of Helicobacter pylori. *Lancet* (1993)342:575-577

93. Wedi B, Kapp A. Helicobacter pylori Infection in Skin Diseases. A Critical Appraisal. *Am J Clin Dermatol* (2002) 3 (4): 273-282
94. Nilius M, Leodolter P, Malfertheiner P. Diagnostische Verfahren bei der Helicobacter pylori Infektion. In: Malfertheiner P (Hg.), Helicobacter pylori - Von der Grundlage zur Therapie. Thieme-Verlag Stuttgart, New York (2000):147-156
95. Varia D, Malfertheiner P, Megraud F, Axon AT, Deltenre M, Gasbarrini G, O'Morain C, Pajares Gercia JM, Quina M, Tytgat GN: Noninvasive antigen-based assay for assessing Helicobacter pylori eradication. The European Helicobacter pylori HpSA Study Group. *Am J Gastroenterolog* (2000) 95 (4):925-929
96. Malfertheiner P. The Maastricht recommendations and their impact on general practice. *Eur J Gastroenterol Hepatol* (1999),11(suppl 2):S63-S67
97. Hollenz M. Die Bedeutung der H. pylori Infektion in der Allgemeinarztpraxis. In: Malfertheiner P (Hg.), Helicobacter pylori - Von der Grundlage zur Therapie. Thieme-Verlag Stuttgart, New York (2000) pp 173-177
98. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. *JAMA* (1994) 272:65-69
99. Bytzer P, Hansen JM, Schaffalitzky de Muckadell OB. Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia. *Lancet* (1994) 343:811-816
100. Silverstein MD, Petterson T, Talley NJ. Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: A decision analysis. *Gastroenterol* (1996) 110:72-83
101. Tebbe B, Schulzke JD, Radenhausen M, Orfanos CE. Bedeutung von Helicobacter pylori bei Dermatosen: Eine aktuelle Bestandsaufnahme. *Deutsches Ärzteblatt* 96, Ausgabe 34-35 vom 30.08.1999 : A-2143 / B-1819 / C-1711
102. Malfertheiner P, Megraud F, O'Morain C, Hungin APS, Jones R, Axon A, Graham DY, Tytgat G, & the european Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 Consensus Report. *Aliment Pharmacol* (2002) 16:167-180
103. Megraud F, Burette A, Glupczynski Y, Fiocca R, Logan R, Quina M, Ericsson S, O'Morain C. Comparison of tests for assessment of Helicobacter pylori eradication: results of a multi-centre study using centralized facility testing. *Eur J Gastroenterol Hepatol* (2000) 12 (6): 629-633
104. Mégraud F, Doermann HP. Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. *Gut*(1998) 43 (Suppl 1):S61-5

105. Michetti P. Zukünftige Entwicklungen in der Therapie. In: Malfertheiner P (Hg.) *Helicobacter pylori - Von der Grundlage zur Therapie*. Thieme-Verlag Stuttgart, New York (2000): 193-196
106. Madani S, Shapiro J. Alopecia areata update. *J Am Acad Dermatol* (2000) 42:549-570
107. Orfanos CE, Garbe C. Häufige Haarkrankheiten. In: Orfanos CE (Hg.), *Therapie der Hautkrankheiten* (2001), Springer-Verlag Heidelberg , pp1396-1402
108. Runne U. Alopecia areata. In: Orfanos CE (Hg.), *Haare und Haarkrankheiten*, Fischer-Verlag Stuttgart (1979): 505-544
109. Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ. Incidence of alopecia areata in Olmsted county, Minnesota, 1975 through 1989. *Mayo Clin Proc* (1995) 70: 628 – 633
110. Muller SA, Winkelmann RK. Alopecia areata: an evaluation of 736 patients. *Arch Dermatol* (1963) 88: 290 – 297
111. Van der Steen P, Boezeman J, Duller P, Happle R. Can Alopecia areata be triggered by emotional stress? An uncontrolled evaluation of 178 patients with extensive hair loss. *Acta Derm Venereol (Stockh)* (1992) 72: 279- 280
112. Skinner RB Jr, Light WH, Bale GF, Rosenburg EW, Leonardi C. Alopecia areata and presence of cytomegalievirus DNA. *JAMA* (1995), 273:1419-1420
113. Mc Elwee KJ, Tobin DJ, Bystyn JC, King LE Jr, Sundberg JP. Alopecia areata: an autoimmune disease? *Exp Dermatol* (1999) 8: 371-79
114. Williams N, Riegert AL. Epidemic alopecia areata. An outbreak in an industrial setting. *Journal of Occupational Medicine* (1971) 13:535-542
115. Swift S. Folie a deux? Simultaneous alopecia areata in a husband and a wife. *Arch Dermatol* (1961) 84:94-96
116. Zalka AD, Byarlay JA, Goldsmith LA. Alopecia à deux: simultaneous occurrence of alopecia in a husband and wife. *Arch Dermatol* (1994) 130:390-392
117. Shellow WV, Edwards JE, Koo JY. Profile of alopecia areata: a questionnaire analysis of patients and family. *Int J Dermatol* (1992) 31:186-189
118. Colombe BW, Price VH, Khoury EL. HLA class II antigen association helps to define two types of alopecia areata. *J Am Acad Dermatol* (1995) 33:157-764
119. Scerri L, Pace JL. Identical twins with alopecia areata. *J Am Acad Dermatol* (1992) 27:766-767

120. Jackow J, Puffer N, Hordinsky M, Nelson J, Tarrand J, Duvic M. Alopecia areata and cytomegalievirus infection in identical twins: genes versus environment? *J Am Acad Dermatol* (1998) 38:418-425
121. Randall VA. Is alopecia areata an autoimmune disease? *Lancet* (2001) 358:1922-1924
122. Rebora A, Drago F, Picciotto A. Helicobacter pylori in patients with rosacea. *Am J Gastroenterol* (1994) 89: 1603-1604
123. Gupta AK, Ellis CN, Cooper KD, Nickoloff BJ, Ho VC, Chan LS, Hamilton TA, Tellner DC, Griffiths CE, Voorhees JJ. Oral cyclosporine for the treatment of alopecia areata. A clinical and immunohistochemical analysis. *J Am Acad Dermatol* (1990) 22:242-250
124. Friedmann PS. Alopecia areata and auto-immunity. *Br J Dermatol* (1981) 105:153-157
125. Duvic M, Nelson A, de Andrade M. The genetics of alopecia areata. *Clin Dermatol* (2001) 19:135-139
126. Colombe BW, Lou CD, Price VH. The genetic basis of alopecia areata: HLA associations with patchy alopecia areata and alopecia universalis. *J Invest Dermatol Symp Proc* (1999) 4:216-219
127. Hoffmann R., Happle R. Alopecia areata, Teil 1: Klinik, Ätiologie, Pathogenese. *Hautarzt* (1999) 50: 222 – 231
128. Orecchia G, Douville H, Marelli MA. Nail changes and alopecia areata. *Ital Gen Rev Dermatol* (1988) 25:179-1784
129. Messenger AG, Slatter DN, Bleehen SS. Alopecia areata: alterations in the hair growth cycle and correlation with the follicular pathology. *Br J Dermatol* (1986) 114:337-347
130. Peereboom-Wynia JDR, Koerten HK, Van Joost TH, Stolz E. Scanning electron microscopy comparing exclamation mark hairs in alopecia areata with normal hair fibers, mechanically broken by traction. *Clin Exp Dermatol* (1989) 14:47-50
131. Perret C, Wiesner-Menzel L, Happle R. Immunohistochemical analysis of T-cell subsets in the peribulbar and intrabulbar infiltrates of alopecia areata. *Acta Derm Venerol* (1984) 64:26-30
132. Wiesner-Menzel L, Happle R. Intrabulbar and peribulbar accumulation of dendritic OKT 6-positive cells in alopecia areata. *Arch Dermatol Res* (1984) 276:333-334
133. Tobin DJ, Orentreich N, Fenton DA, Bystryjn JC. Antibodies to hair follicles in Alopecia areata. *J Invest Dermatol* (1994) 102: 721- 724
134. Tobin DJ, Hann S, Song M, Bystryjn JC. Hair follicle structures targeted by antibodies in patients with alopecia areata. *Arch Dermatol* (1997) 133:57-61

135. Gilhar A, Ullmann Y, Berkutzki T, Assy B, Kalish RS. Autoimmune hair loss (Alopecia areata) transferred by T-lymphocytes to human scalp explants on SCID mice. *J Clin Invest* (1998)101:62-67
136. Mc Elwee KJ, Spiers EM, Oliver RF. In vivo depletion of CD8+ T cells restores hair growth in the DEBR model for alopecia areata. *Br J Dermatol* (1995) 135:211-217
137. Philpott MP, Sanders DA, Bowen J, Kealy T. Effects of interleukins, colony-stimulating factor and tumor necrosis factor on human hair follicle growth in vitro: a possible role for interleukin -1 and tumor necrosis factor- α in alopecia areata. *Br J Dermatol* (1996) 135:942-948
138. Mosmann TR, Cofmann RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different function properties. *Annu Rev Immunol* (1989) 7:145-173
139. Hoffmann R, Eicheler W, Huth A, Wenzel E, Happle R. Cytokines and growth factors influence hair growth in vitro: possible implications for the pathogenesis and treatment of alopecia areata. *Arch Dermatol Res* (1996) 288:153-156
140. Hsoi J, Murphy GF, Egan CL, Lerner EA, Grabbe S, Asahina A, Granstein RD. Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide. *Nature* (1993) 363:159-163
141. Lindemayr W. Ätiologische Probleme bei chronischer Urticaria. 1. Mitteilung: Die Bedeutung des Gastrointestinaltraktes. *Dermatol Wochenschr* (1954) 130:1343-1352
142. Lindemayr W. Ätiologische Probleme bei chronischer Urticaria. 2. Mitteilung: Die Bedeutung der bakteriellen Infektion. *Dermatol Wochenschr* (1955) 132: 865-871
143. Leotiadis GI, Sharma VK, Howden CW. Non-Gastrointestinal Tract Associations of *Helicobacter pylori* Infection. *Arch Intern Med* (1999) 159:925-940
144. Rothenbacher D, Bode G, Winz T, Berg G, Adler G, Brenner H. *Helicobacter pylori* in out-patients of a general practitioner: prevalence and determinants of current infection. *Epidemiol Infect* (1997) 119:151-157
145. Breuer T, Sudhop T, Hoch J, Sauerbruch T, Malfertheiner P. Prevalence of and risk factors for *Helicobacter pylori* infection in the western part of Germany. *Eur J Gastroenterol Hepatol* (1996) 8:47-52
146. Wedi B, Wagner S, Werfel T, Manns MP, Kapp A: Prevalence of *Helicobacter pylori*-associated gastritis in chronic urticaria. *Int Arch Allergy Immunol* (1998) 116:288-294
147. Tebbe DN, Geilen CC, Schulzke JD, Bojarski C, Radenhausen M, Orfanos CE. *Helicobacter pylori* infection and chronic urticaria. *J Am Acad Dermatol* (1996) 34:685-686

148. Dominci P, Bellentani S, Di Biase AR, Saccoccio G, Le Rose A, Masutti F, Viola L, Balli F, Tiribelli C, Grilli R, Fusillo M, Grossi E. Familial clustering of *Helicobacter pylori* infection: a population based study. *BMJ* (1999) 319: 537-541
149. Stone MA, Patel H, Panja KK, Barnett DB, Mayberry JF. Results of *Helicobacter pylori* screening and eradication in a multi-ethnic community in central England. *Eur J Gastroenterol Hepatol* (1998) 10: 957-962
150. Crabtree JE, O'Mahony S, Wyatt JI, Heatley RV, Vestey JP, Howdle PD, Rathbone BJ, Losowsky MS. *Helicobacter pylori* serology in patients with coeliac disease and dermatitis hepeticiformis. *J Clin Pathol* (1992) 45:579-600
151. Kosunen TU, Aromaa A, Knekt P, Salomaa A, Rautelin H, Lohi P, Heinonen OP. *Helicobacter* antibodies in 1973 and 1994 in the adult population of Vammala, Finland. *Epidemiol Infect* (1997) 119: 29-34
152. Collin P, Karvonen AL, Korpela M, Laippala P, Helin H. Gastritis classified in accordance with the Sydney system in patients with primary Sjögren's syndrome. *Scand J Gastroenterol* (1997) 32:108-111
153. Us D, Hascelik G. Seroprevalence of *Helicobacter pylori* infection in an asymptomatic Turkish population. *J Infect* (1998)3:148-150
154. Utas S, Özbakir Ö, Turasan A, Utas C. *Helicobacter pylori* eradication treatment reduces the severity of rosacea. *J Am Acad Dermatol* (1999) 40:433-435
155. Avci O, Ellidokuz E, Simsek I, Buyukgebiz B, Gunes AT. *Helicobacter pylori* and Behçet disease. *Dermatology* (1999) 199:104-103
156. Hyams KC, Tylor DN, Gray CC, Knowles JB, Hawkins R, Malone JD. The risk of *Helicobacter pylori* infection among U.S. military personnel deployed outside the United States. *Am J Trop Med Hyg* (1995) 52:109-112
157. Bamford JT, Tilden RL, Blankush JL, Gangeness DE. Effect of treatment of *Helicobacter pylori* infection on rosacea. *Arch Dermatol* (1999) 135:659-663
158. Jones MP, Knable Jr AL, White MJ, Durning SJ. *Helicobacter pylori* in Rosacea: lack of an association. *Arch Dermatol* (1998) 134:511
159. Sharma VK, Lynn A, Kaminski M, Vasudeva R, Howden CW. A study of the *Helicobacter pylori* infection and other markers of upper gastrointestinal tract disease in patients with rosacea. *Am J Gastroenterol* (1998) 93:220-222
160. Halasz CLG. *Helicobacter pylori* antibodies in patients with psoriasis. *Arch Dermatol* (1996) 132:95-96

161. Fujisawa T, Kumagai T, Akamatsu T, Kiyosawa K, Matsunaga Y. Changes in seroepidemiological pattern of *Helicobacter pylori* and hepatitis A virus over the last 20 years in Japan. *Am J Gastroenterol* (1999) 94:2094-2099
162. Yazawa N, Fujimoto M, Kikuchi K, Kubo M, Ihn H, Sato S, Tamaki K. High seroprevalence of *Helicobacter pylori* infection in patients with systemic sclerosis: Association with esophagol involvement. *J Rheumatol* (1998) 25:650-653
163. Shiotani A, Okada K, Yanaoka K, Itoh H, Nishioka S, Sakurane M, Matasunaka M. Beneficial Effect of *Helicobacter pylori* Eradication in Dermatologic Diseases. *Helicobacter* (2001) 6:60-65
164. Murakami K, Fujikota T, Nishizono A, Nagai J, Tokieda M, Kodama R, Kubota T, Nasu M. Atopic dermatitis successfully treated by eradication of *Helicobacter pylori*. *J Gastroenterol* (1996) 31: 77 – 82
165. Reinauer S, Megahed M, Goerz G, Ruzicka T, Borchard F, Susanto F, Reinauer H. Schönlein- Henoch purpura associated with gastric *Helicobacter pylori* infection. *J Am Acad Dermatol* (1995) 33:876-879
166. Machet L, Vaillant L, Machet MC, Buchler M, Lorette G . Schoenlein-Henoch purpura associated with gastric *Helicobacter pylori* infection. *Dermatology* (1997) 194 (1):86
167. Moczczynas R, D`Amore ES, Montini G, Guariso G. Schoenlein-Henoch vasculitis and chronic *Helicobacter pylori* associated gastritis and duodenal ulcer: a case report. *Pediatr Med Chir* (1997) 19: 476-478
168. Cecchi R, Torelli E. Schoenlein-Henoch purpura in association with duodenal ulcer and gastric *Helicobacter pylori* infection. *J Dermatol* (1998)25:482-4
169. Reinauer S, Goerz G, Ruzicka T, Susanto F, Humfeld S, Reinauer H. *Helicobacter pylori* in patients with systemic sclerosis: detection with the ¹³C-urea breath test and eradication. *Acta Derm Venerol* (1994) 74:361-363
170. Kurkcüoglu N, Aksoy F: Sweet's syndrome associated with *Helicobacter pylori* infection. *J Am Acad Dermatol* (1997) 37:123 – 124
171. Figura N, Giordano N, Burroni D. Sjögren's syndrome and *Helicobacter pylori* infection. *Eur J Gastroenterol Hepatol* (1994) 2:437-444
172. Knipp U, Opferkuch W. Immunologie der *Helicobacter- pylori* - Infektion. Die gelben Hefte (1995) 35:104-111
173. Wee A, Teh M, Kang JY. Association of *Helicobacter pylori* with HLA-DR antigen expression in gastritis. *J Clin Path* (1992) 45: 30-33

174. Del Giudice G, Covacci A, Telford JL, Montecucco C, Rappuoli R. The design of vaccines against *Helicobacter pylori* and their development. *Annu Rev Immunol* (2001) 19:523-563
175. Leung DYM, Hauk P, Strickland I, Travers JB, Norris DA. The role of superantigens in human diseases: therapeutic implications for the treatment of skin diseases. *Br J Dermatol* (1998) 139:17-29
176. Fukuda Y, Bamba H, Okui M, Tamura K, Tanida N, Satomi M, Shimoyama T, Nishigami T. *Helicobacter pylori* infection increases mucosal permeability of the stomach and intestine. *Digestion* (2001) 63: 93-96
177. Kurose I, Granger DN, Evans Jr DJ, Evans DG, Graham DY, Miyasaka M, Anderson DC, Wolf RE, Cepinskas G, Kvietys PR. *Helicobacter pylori*-induced microvascular protein leakage in rats: role of neutrophils, mast cells, and platelets. *Gastroenterology* (1994) 107:70-79
178. Zito F, Di Castelnuovo A, D'Orazio A, Negrini R, De Lucia D, Donati MB, Iacoviello L. *Helicobacter pylori* infection and the risk of myocardial infarction: role of fibrinogen and its genetic control. *Thromb Haemost* (1999) 82:14-18
179. Elizalde JJ, Gomez J, Panes J, Lozano M, Casadevall M, Ramirez J, Pizcueta P, Marco F, Rojas FD, Granger DN, Pique JM. Platelet activation in mice and human *Helicobacter pylori* infection. *J Clin Invest* (1997) 100:996-1005
180. Hizal M, Tuzun B, Wolf R, Tuzun Y. The relationship between *Helicobacter pylori* IgG antibody and autologous serum test in chronic urticaria. *Int J Dermatol* (2000) 39:443-445
181. Liekenbröcker T, Koerner M, Kapp A, Wedi B. Correlation between infect-associated urticaria with positive autologous serum skin test. *Allergologie* (2001) 24:475-479
182. Negrini R, Savio A, Poiesi C, Appelmelk BJ, Buffoli F, Paterlini A, Cesari P, Graffeo M, Vaira D, Franzin G. Antigenic mimicry between *Helicobacter pylori* and gastric mucosa in the pathogenesis of body atrophic gastritis. *Gastroenterology* (1996) 111:655-665
183. Boren T, Falk P, Roth LA, Larson G, Normark S. Attachment of *Helicobacter pylori* to human gastric epithelium mediated by blood group antigens. *Science* (1993) 262:321-322
184. Ilver D, Arnqvist A, Ogren J, Frick IM, Kersulyte D, Incecik ET, Berg DE, Covacci A, Engstrand L, Boren T. *Helicobacter pylori* adhesin binding fucosylated histo-blood group antigens revealed by retagging. *Science* (1998) 279:373-377
185. Tosti A, Pretolani S, Figura N, Polini M, Cameli N, Cariani G, Miglio F, Bonvinci B, Baldini L, Gnucchi E, Lucente P, Gasbarrini G. *Helicobacter pylori* und skin diseases. *Gastroenterol Int* (1997) 10 (suppl 1): 37-39

186. Rigopoulos D, Katsambas A, Karalexis A, Papatheodorou G, Rokkas T. No increased prevalence of *Helicobacter pylori* in patients with alopecia areata. *J Am Acad Dermatol* (2002) 46(1):141
187. Pilowsky I, Spence ND. Ethnicity and illness behaviour. *Psychol Med* (1977) 7(3):447-452
188. Yamaoka N, Kodama T, Kashima K, Graham DY, Sepulveda AR. Variants of the 3' region of the *cagA* gene in *Helicobacter pylori* isolates from patients with different *H.pylori*-associated diseases. *J Clin Microbiol* (1998) 36:2258-2263
189. Perez-Perez I, Bhat N, Gaesbauer J, Fraser A, Taylor DN, Kuipers EJ, Zhang L, You WC, Blaser MJ. Country-specific constancy by age in *cagA*+ porportion of *Helicobacter pylori* infections. *Int J Cancer* (1997) 72:453-456
190. Perez-Perez I, Salomaa A, Kosunen TU, Davermann B, Rautelin H, Aromaa A, Knekt P, Blaser MJ. Evidence that *cagA*+ *Helicobacter pylori* strains are disappearing more rapidly than *cagA* - strains. *Gut* (2002) 50:295-298
191. Gordis L. *Epidemiologie und Politik in: Epidemiologie*, Verlag im Kilian, Marburg, 1. deutschsprachige Auflage (2001):330- 343
192. De Koster E, De Bruyne I, Langlet P, Deltenre M. Evidence based medicine and extradigestive manifestations of *Helicobacter pylori*. *Acta Gastroenterol Belg* (2000) 63 (4): 388-392
193. van der Ende A, Pan ZJ, Bart A, van der Hulst RW, Feller M, Xiao SD, Tytgat GN, Dankert J. *cagA*-positive *Helicobacter pylori* populations in China and The Netherlands are distinct. *Infect Immun* (1998) 66:1822-1826
194. Evans DJ, Evans DG. *Helicobacter pylori CagA: Analysis of Sequence Diversity in Relation to Phosphorylation Motifs and Implications for the Role of CagA as a Virulence Factor*. *Helicobacter* (2001) 6:187-198
195. Crabtree JE, Kersulyte D, Li S, Lindley IJ, Berg DE. Modulation of *Helicobacter pylori* induced interleukin -8 synthesis in gastric epithelial cells mediated by *cag PAI* encode *VirD4* homologue. *J Clin Pathol* (1999) 52:653-657
196. Audibert C, Janvier B, Grignon B, Salaun L, Burucoa C, Lecron JC, Fauchere JL. Correlation between IL-8 induction, *cagA* status and *vacA* genotypes in 153 French *Helicobacter pylori* isolates. *Res Microbiol* (2000) 151:191-200
197. Labenz J, Blum AL, Bayerdörffer E, Meining A, Stolte M, Börsch G: Curing *Helicobacter pylori* infection in patients with duodenal ulcer may provoke reflux esophagitis. *Gastroenterology* 112(1997)1442- 1447

198. Wartburton-Timms VJ, Charlett A, Valori RM, Uff JS, Shephers NA, Barr H, Mc Nulty CAM. The significance of cagA positive *Helicobacter pylori* in reflux esophagitis. *Gut* (2001) 49:341-346
199. Richter JE. *H. pylori*: the bug is not all bad. *Gut*(2001)49:319-321
200. Widmer M, de Korwin JD, Aucher P, Thiberge JM, Suerbaum S, Labigne A, Fauchere JL. Performance of native and recombinant antigens for diagnosis of *Helicobacter pylori* infection. *Eur J Clin Microbiol Infect Dis* (1999) 18:823-827
201. Lewala-Guruge J, Kreger AS, Ljungh A, Wadsrom T. Immunological properties of the cell surface haemagglutinins (sHAs) of *Helicobacter pylori* strain NCTC 11637. *FEMS Immunol and Med Microbiol* (1995) 11:73-77
202. Doig P, Trust TJ. Identification of surface-exposed outer membrane antigens of *Helicobacter pylori*. *Infect Immun* (1994) 62:4526-4533
203. Ferrero RL, Thiberge JM, Kansau I, Wuscher M, Huerre M, Labigne A. The GroES homolog of *Helicobacter pylori* confers protective immunity against mucosal infection in mice. *Proc Natl Acad Sci USA* (1995) 92:6499-6503
204. Guruge JL, Schalen C, Nilsson I, Ljungh A, Tyszkiewicz T, Wikander M, Wadstrom T. Detection of antibodies to *Helicobacter pylori* cell surface antigens. *Scand J Infect Dis* (1990) 22:457-465
205. SuerbaumS, Thiberge JM, Kansau I, Ferrero RL, Labigne A. *Helicobacter pylori* hspA-hspB heat-shock gene cluster: nucleotide sequence, expression, putative function and immunogenicity. *Mol Microbiol* (1994) 14:959-974
206. Kansau I, Labigne A. Heat shock proteins of *Helicobacter pylori*. *Aliment Pharmacol Ther* (1996) 10, Suppl 1:51-56
207. Kersulyte D, Mudhopadhyay AK, Velapino B, Su W, Pan Z, Garcia C, Hernandez V, Valdez Y, Mistry RS, Gilman RH, Yuan Y, Gao H, Alarcon T, Lopez-Brea M, Balakrish Nair G, Chowdhury A, Datta S, Shirai M, Nakazawa T, Ally R, Segal I, Wong BC, Lam SK, Olfat FO, Boren T, Engstrand L, Torres O, Schneider R, Thomas JE, Czinn S, Berg DE. Differences in genotypes of *Helicobacter pylori* from different human population. *J Bacteriol* (2000)182:3210-3218
208. Muller I, Medina-Selby A, Palacios JL, Martinez P, Opazo P, Bruce E, Mancilla M, Valenzuela P, Yudelevich A, Venegas A. Cloning and comparison of ten gene sequences of a Chilean *H. Pylori* strain with other *H. pylori* strains revealed higher variability for VacA and CagA virulence factors. *Biol Res* (2002) 35 (1): 67-84
209. Newell DG, Stacey A. Antigen for the serodiagnosis of *Campylobacter pylori* infection. *Gastroenterol Clin Biolog* (1989) 13:37B-41B

210. Vaucher C, Janvier B, Nousbaum JB, Grignon B, Pezennec L, Robaszkiewicz M, Gouerou H, Picard B, Fauchere JL. Antibody response of patients with Helicobacter pylori-related gastric adenocarcinoma: Significance of anti-CagA antibodies. *Clin Diag Lab Immunol* (2000) 7:463-467
211. Megraud F. The most important diagnostic modalities for Helicobacter pylori, now and in the future. *Eur J Gastroenterol Hepatol* (1997) 9, Suppl 1: 13-15
212. van den Oever HL, Loffeld RJ, Stobberingh EE: Usefulness of a new serological test (Bio-Rad) to diagnose Helicobacter pylori – associated gastritis. *J Clin Microbiol* (1991) 29:283-286
213. Crabtree JE, Mahony MJ, Taylor JD, Heatly RV, Littlewood JM, Tompkins DS. Immune response to Helicobacter pylori in children with recurrent abdominal pain. *J Clin Pathol* (1991) 44:768-771
214. Sobala GM, Crabtree JE, Dixon MF, Schorah CJ, Taylor JD, Rathbone BJ, Heatly RV, Axon AT. Acute Helicobacter infection: clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice asorbic acid concentrations. *Gut* (1991)32:1415-1418
215. de Oliveira AM, Rocha GA, Queiroz DM, Mendes EN, de Carvalho AS, Ferrari TC, Nogueira AM. Evaluation of enzyme - linked immunosorbent assay for the diagnosis of Helicobacter pylori infection in children from different age groups with or without duodenal ulcer. *J Pediatr Gastroenterol Nutr* (1999) 28 :157-161
216. Kokkola A, Rautelin H, Puolakkainen P, Sipponen P, Farkila M, Konsunen TU. Positive result by serology indicates active Helicobacter pylori infection in patients with atrophic gastritis. *J Clin Microbiol* (1998) 36:1808-1810
217. Lerang F, Moum B, Mowinckel P, Haug JB, Ragnhilstveit E, Berge T, Bjorneklett A. Accuracy of seven different tests for the diagnosis of Helicobacter pylori infection and the impact of H2-receptor antagonists on the test results. *Scan J Gastroenterol* (1998) 33:364-369
218. Logan RP, Walker MM, Misiewicz JJ, Gummet PA, Karim QN, Baron JH. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. *Gut* (1995) 36:12-16
219. Van Doorn LJ, Quint W, Schneeberger P, Tytgat GM, de Boer WA. The only good Helicobacter pylori is a dead Helicobacter pylori. *Lancet* (1997)350:71-72
220. Marais A, Monteiro L, Lamouliate H, Samoyeau R, Megraud F. Cag A negative Status of Helicobacter pylori is a risk factor for failure of PPI-based triple therapies in non-ulcer dyspepsia. *Gastroenterology* (1998) 114:A 214

221. Mitchell HM, Hazell SL, Li YY, Hu PJ. Serological response to specific *Helicobacter pylori* antigens: antibody against CagA is not predictive of gastric cancer in a developing country. *Am J Gastroenterol* (1996) 91:1785-1788
222. McDonagh AJG, Tazi.Ahnini R. Epidemiology and genetics of alopecia areata. *Clin Experimen Dermatol* (2002) 27:405-409
223. Tarlow JK, Clay FE, Cork MJ, Blakemore AIF, McDonagh AJG, Messenger AG; Duff GW. Severity of alopecia areata is associated with a polymorphism in the interleukin-1 receptor antagonist gene. *J Invest Dermatol* (1994) 103:387- 390
224. Galbraight GM, Miller D, Emerson DL. Tumor necrosis factor alpha (TNF- alpha) gene polymorphism in alopecia areata. *Hum Genet* (1996)96: 433- 436
225. Betterle C, Greggio NA, Volpato M. Autoimmune polyglandular syndrome type 1. *J Clin Endocrinol Metab* (1998) 83:1049-1055
226. Yea SS, Yang YI, Jang WH, Lee YJ, Bae HS, Paik KH. Association between TNF-
alpha promoter polymorphism and *Helicobacter pylori* cagA subtype infection. *J Clin Pathol* (2001) 54(9):703-706
227. Olsen EA, Carson SC, Turney EA. Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. *Arch Dermatol* (1992) 128:1467-1473